Benzinga
Benzinga
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Benzinga
martes, septiembre 01
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
IDEXX Laboratories Inc
IDXX
NASDAQ
Lista de seguimiento
Get Report
Trade with Public
Get Report
Trade with Public
$556.69
1.70
0.31%
al cierre: Aug 28, 5:00 PM EST
$556.69
1.70
0.31%
Premercado: 5:13 AM EST
Get Report
Panorámica general
Noticias
Previsión de beneficios
Eventos
Precios objetivo
Finanzas
Sentimiento
Propiedad
Comparar
Opciones
Informe de acciones
IDEXX Laboratories Financials
IDEXX Laboratories (IDXX) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
Why Is IDEXX Laboratories Stock Gaining Tuesday?
IDEXX Laboratories (IDXX) stock rose after reporting Q2 earnings of $4.27/share and $1.22B in revenue, beating Wall Street estimates.
Vandana Singh
PRO
IDEXX Laboratories Raises FY2026 GAAP EPS Guidance from $14.45-$14.90 to $14.69-$14.94 vs $14.67 Est; Narrows FY2026 Sales Guidance from $4.675B-$4.760B to $4.700B-$4.745B vs $4.711B Est
IDEXX Laboratories (NASDAQ:IDXX) raises FY2026 GAAP EPS guidance from $14.45-$14.90 to $14.69-$14.94 vs $14.67 analyst estimate. Narrows FY2026 sales outlook from $4.675 billion-$4.760 billion to $4.700 billion-$4.745
Benzinga Newsdesk
PRO
IDEXX Laboratories Q2 EPS $4.27 Beats $3.96 Estimate, Sales $1.217B Beat $1.201B Estimate
IDEXX Laboratories (NASDAQ:IDXX) reported quarterly earnings of $4.27 per share which beat the analyst consensus estimate of $3.96 by 7.83 percent. This is a 17.63 percent increase over earnings of $3.63 per share from
Benzinga Newsdesk
Idexx Laboratories Raises Guidance On Higher Clinical Visits, Diagnostic Frequency
Idexx Laboratories shares edge higher as revenue tops estimates but earnings per share misses; guidance raised.
Vandana Singh
PRO
CORRECTION: IDEXX Laboratories Q1 EPS $3.47 Beats $3.41 Estimate, Sales $1.141B Beat $1.109B Estimate
IDEXX Laboratories (NASDAQ:IDXX) reported quarterly earnings of $3.47 per share which beat the analyst consensus estimate of $3.41 by 1.76 percent. This is a 20.91 percent increase over earnings of $2.87 per share from
Benzinga Newsdesk
Earnings Scheduled For May 5, 2026
Benzinga Insights
Privacy Manager